First Trust Exchange-Traded Fund III First Trust SMID Growth Strength ETF FSGS 深 滬
等待開盤 09-06 09:30:00 美东时间
31.5746
-0.020
-0.06%
華盛通- 最 高31.78
- 今 開31.78
- 成交量 372股
- 最 低 31.40
- 昨 收 31.5945
- 總市值 3157.46万
- 52周最高 32.5669
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 24.39
- 委 比 11.11%
- 總股本 100.00万
- 歷史最高 32.5669
- 量 比 0.02
- 振 幅 1.20%
- 歷史最低 9.9631
- 每 手 1
- 風險率 1.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.
08-29 00:40
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (6 Ratings)
6 analysts have shared their evaluations of Travere Therapeutics (NASDAQ:TVTX) ...
08-28 20:00
ZyVersa Highlights Review Of 172 Studies Linking Lipotoxicity To DKD Progression; Supports Therapeutic Targeting Of Lipid Metabolic Reprogramming
Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis that cause progressive kidney damage and disease progression.Earlier data by Kanbay et al (Eur
08-14 19:58
Earnings Preview: Travere Therapeutics
Travere Therapeutics (NASDAQ:TVTX) is gearing up to announce its quarterly earn...
08-06 03:10
ZyVersa Therapeutics Releases Mid-Year Shareholder Letter Highlighting Recent Corporate Developments And R&D Progress Including Closing Two Financial Transactions Providing Access To $12M In Capital
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have
07-21 20:04
Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?
ZyVersa gains FDA approval for emergency use of VAR 200 in a rare kidney disease case; stock jumps on high trading volume and regulatory momentum.
07-09 01:48
Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews
During the last three months, 8 analysts shared their evaluations of Travere Th...
07-02 05:01
7 Analysts Assess Travere Therapeutics: What You Need To Know
Providing a diverse range of perspectives from bullish to bearish, 7 analysts h...
06-11 20:00
Travere Therapeutics Reports SPARTACUS And PROTECT OLE Data Showing FILSPARI's Proteinuria Reduction And IgA Protection
Data from SPARTACUS and PROTECT OLE to show significant proteinuria reduction when replacing RASi with FILSPARI and when FILSPARI is used in combination with SGLT2iNew mechanistic data to show FILSPARI protects against
06-04 04:33
Travere Therapeutics Receives FDA Acceptance Of Supplemental New Drug Application For FILSPARI In FSGS
PDUFA target action date of January 13, 2026If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure
05-16 04:09
